FY2024 Earnings Estimate for MLYS Issued By Lifesci Capital

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Equities research analysts at Lifesci Capital decreased their FY2024 earnings per share estimates for Mineralys Therapeutics in a note issued to investors on Tuesday, November 12th. Lifesci Capital analyst R. Katkhuda now forecasts that the company will earn ($3.87) per share for the year, down from their previous estimate of ($3.28). The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($3.50) per share. Lifesci Capital also issued estimates for Mineralys Therapeutics’ Q4 2024 earnings at ($1.17) EPS.

Separately, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a research note on Tuesday.

Mineralys Therapeutics Trading Down 5.7 %

NASDAQ MLYS opened at $11.48 on Thursday. The firm has a market capitalization of $571.36 million, a P/E ratio of -3.62 and a beta of 1.71. The firm’s fifty day moving average price is $12.99 and its two-hundred day moving average price is $12.65. Mineralys Therapeutics has a 1 year low of $5.85 and a 1 year high of $16.91.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings data on Monday, November 11th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.30). During the same period in the prior year, the company posted ($0.57) earnings per share.

Institutional Trading of Mineralys Therapeutics

Several hedge funds have recently added to or reduced their stakes in MLYS. RA Capital Management L.P. grew its holdings in Mineralys Therapeutics by 52.6% in the 1st quarter. RA Capital Management L.P. now owns 4,850,984 shares of the company’s stock valued at $62,626,000 after buying an additional 1,672,508 shares in the last quarter. SR One Capital Management LP grew its stake in shares of Mineralys Therapeutics by 12.4% in the first quarter. SR One Capital Management LP now owns 2,016,822 shares of the company’s stock valued at $26,037,000 after acquiring an additional 222,222 shares in the last quarter. Vanguard Group Inc. increased its position in Mineralys Therapeutics by 0.5% during the first quarter. Vanguard Group Inc. now owns 982,932 shares of the company’s stock worth $12,690,000 after acquiring an additional 4,952 shares during the period. Caligan Partners LP increased its position in Mineralys Therapeutics by 31.6% during the third quarter. Caligan Partners LP now owns 981,155 shares of the company’s stock worth $11,882,000 after acquiring an additional 235,397 shares during the period. Finally, American Century Companies Inc. raised its stake in Mineralys Therapeutics by 3.2% in the 2nd quarter. American Century Companies Inc. now owns 743,140 shares of the company’s stock worth $8,695,000 after purchasing an additional 23,170 shares in the last quarter. 84.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider David Malcom Rodman sold 25,482 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $15.03, for a total transaction of $382,994.46. Following the completion of the sale, the insider now owns 135,974 shares in the company, valued at approximately $2,043,689.22. This trade represents a 15.78 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Jon Congleton sold 15,271 shares of Mineralys Therapeutics stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $13.52, for a total transaction of $206,463.92. Following the sale, the chief executive officer now directly owns 895,941 shares of the company’s stock, valued at $12,113,122.32. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 51,510 shares of company stock valued at $735,431 over the last three months. Insiders own 33.24% of the company’s stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.